This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Nanexa AB (publ)
Q12026
4/29/2026
Moderator
Host/Investor Relations
Welcome, Nanexa has released a report for the first quarter of 2026 and next to my studio I have the CEO David Westberg. He will give comments on results and activities as well as preclinical data. An analyst will also be present at the question time afterwards and we will of course take up a whole lot of all the questions that come in in the live chat. Welcome David. Thank you very much. Before you present, it feels like you're going from hot through hotter. How do you describe the situation right now?
David Westberg
CEO
I think that was a really good description. We have wind in the sails. There are a lot of good activities at the lab in those areas. The collaboration we have with different companies, and we have the results that I will talk about in a bit, for Semaglutid, and that is really hot. And we have ongoing, I call it discussions, negotiations, you can use different names for it, with a number of companies. It's an intense period, and a fun period, I would say.
Moderator
Host/Investor Relations
Okay, with that, please go ahead and present, and I'll see you in a moment.
You're reading a preview of the NANEXA.ST Q1 2026 earnings call.
Free account.
Disclaimer